Press & News

The latest announcements from Babson Diagnostics, a medical technology company with a new vision for diagnostic blood testing.

  1. Sept. 24 2020

    Babson Diagnostics Appoints Former Siemens Healthineers Executive to CEO

    Babson Diagnostics (Babson), a transformative medical technology company, has appointed David Stein, Ph.D., former head of global strategy and innovation at Siemens Healthineers, to chief executive officer. Eric Olson, Babson’s founder and former CEO, will assume the roles of chairman of the board and chief operating officer...

  2. Sept. 24 2020

    Babson Diagnostics Closes $13.7 Million Series A to Democratize Diagnostic Blood Testing

    Babson Diagnostics (Babson), a transformative medical technology company, announced today it closed $13.7 million in cumulative Series A funding, led by Siemens Healthineers, Prism Ventures, Genesis Merchant Capital, and Lago Consulting Group. Originally incubated at Siemens Healthineers and developed in partnership with Becton Dickinson, Babson’s disruptive technology is designed to analyze capillary blood samples using ...

  3. Jun. 25 2020

    Babson Diagnostics Receives FDA Emergency Use Authorization for its SARS-CoV-2 IgG Antibody Test

    Babson Diagnostics (Babson), a transformative diagnostic blood testing company, announced today that its SARS-CoV-2 IgG antibody test, Babson Diagnostics aC19G1, has received emergency use authorization (EUA) from the Food and Drug Administration (FDA). Babson Diagnostics aC19G1 is a COVID-19 serology test that enables the qualitative detection of IgG antibodies to SARS-CoV-2 with 100% sensitivity and 100% specificity. The test is designed to aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior COVID-19 infection...

  4. May 20 2020

    Babson Diagnostics Enters Collaborative Research Agreement with Dell Medical School to Study Immune Response to COVID-19

    Babson Diagnostics (Babson), a transformative diagnostic blood testing company, announced today it has entered into a collaborative research agreement with Dell Medical School at The University of Texas at Austin (Dell Med) to study the immune response to COVID-19. The announcement follows the recent launch of Babson’s IgG serology test, which yielded 93.2 percent sensitivity and 100.0 percent specificity in its clinical performance evaluation and has...

  5. Apr. 30 2020

    Babson Diagnostics Launches COVID-19 Serology Test for IgG Antibodies with 100% Specificity in Austin

    Babson Diagnostics, Inc., announced today it has launched its first COVID-19 serology test to detect IgG antibodies to SARS-CoV-2 in the bloodstream through a select network of retail and clinical partners in Austin, Texas. Clinical performance evaluation for Babson’s IgG assay resulted in 93.2 percent sensitivity and 100.0 percent specificity....

  6. Apr. 15 2020

    Babson Diagnostics to Offer High-Throughput COVID-19 Serology Testing in Austin, Texas

    Babson Diagnostics, Inc., announced today it will launch a COVID-19 serology testing service. COVID-19 serology testing is used to detect the presence of antibodies to SARS-CoV-2 in the bloodstream, which makes it the preferred method for evaluating whether a person has had a SARS-CoV-2 infection in the past...

  7. Mar. 11 2020

    Babson Diagnostics Bolsters Board of Directors with Three Diagnostics Industry Experts

    Babson Diagnostics, Inc., announced today that it has expanded its board of directors to include diagnostics industry leaders David Stein (Director), Dennis Gilbert (Director), and Dave Hickey (Observer). The additions reinforce Babson’s origins within and connections to some of the world’s leading diagnostics companies and emphasize the company’s dedication to leading through science...

  8. Feb. 12 2020

    BD, Babson Diagnostics Announce Strategic Partnership Agreement to Enable Small-Volume Blood Collection for Diagnostic Testing in Retail Settings

    BD (Becton, Dickinson and Company), a leading global medical technology company and Babson Diagnostics, a transformative diagnostic blood testing company, today announced a long-term strategic partnership agreement to bring laboratory-quality, small-volume blood collection to retail pharmacies...

  9. Jul. 30 2019

    Babson Diagnostics announces its Scientific Advisory Board

    Babson Diagnostics, Inc., has established its Scientific Advisory Board. Drs. Alan Wu, Susan A. Evans, and Robert H. Christenson will join the Babson team as scientific advisors. These three celebrated scientists will contribute their experience and expertise to guide Babson Diagnostics...

  10. May 23 2019

    Babson Diagnostics wins Austin A‑List Award

    Babson Diagnostics, Inc., was named a winner at the Greater Austin Chamber of Commerce’s 2019 Austin A-List Awards, “Austin’s premiere honor for homegrown companies.” The A-List honors 24 local companies in various stages of growth that demonstrate cutting-edge innovation, achievable goals, sustainable practices, scalability, and leadership...

  11. May 14 2019

    Babson Diagnostics welcomes Mini Kahlon to its Board of Directors

    Babson Diagnostics, Inc., welcomed Mini Kahlon as the newest member of its Board of Directors. Regarding her commitment to Babson’s success, Mini expressed, “I believe the space Babson is moving into has significant potential to move the cost and experience curves, and is essential to the vision of delivering healthcare...

  12. Mar. 11 2019

    Babson Diagnostics featured in Capital City Innovation Annual Report

    Babson Diagnostics, Inc., was featured today in Capital City Innovation's 2018 Annual Review. Capital City Innovation is a 501(c)(3) nonprofit focused on cultivating collaboration and growth in Austin's Innovation District, the thriving downtown area that includes UT Austin and Dell Seton Medical Center...

  13. Oct. 19 2018

    Babson Diagnostics secures $3.5 million in Series A financing from Prism Ventures

    Babson Diagnostics, Inc., a healthcare technology company focused on moving laboratory testing to the pharmacy counter, secured $3.5 million in Series A financing on October 4 from Prism Ventures, a New York-based advisory and investment firm specializing in life sciences...

Media contact

For PR and media inquiries, please reach out to

Keep Up with Our Latest News

Sign up to subscribe to our mailing list, and receive company updates sent straight to your inbox.

Oops! Something went wrong with your subscription. Please try again.
Thanks for signing up!